Moreover, sequential chemotherapy, which are commonly used in advanced GC patients, might also induce DNA damage in stromal cells, resulting in the activation of NF-κB, eventually contributing to therapeutic resistance [54]. This evidence concerns the gene NFKB1 and gastric cancer.